Literature DB >> 24732335

To B-(RAF) or not to be.

Reinhard Dummer1, Simone M Goldinger2, Daniel Widmer2, Jil Dreier2, Mitchell P Levesque2.   

Abstract

The identification of targetable mutations has revolutionized the therapy of metastatic melanoma. In particular, BRAF and MEK inhibitors have a well-documented impact on overall survival in metastatic disease. However, therapeutic success is highly dependent on the correct identification of these mutations. We discuss the impact of molecular heterogeneity in this context.

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24732335     DOI： 10.1038/jid.2014.62

Source DB:  PubMed          Journal:  J Invest Dermatol        ISSN： 0022-202X            Impact factor:   8.551


  15 in total

1.  Improved survival with MEK inhibition in BRAF-mutated melanoma.

Authors:  Keith T Flaherty; Caroline Robert; Peter Hersey; Paul Nathan; Claus Garbe; Mohammed Milhem; Lev V Demidov; Jessica C Hassel; Piotr Rutkowski; Peter Mohr; Reinhard Dummer; Uwe Trefzer; James M G Larkin; Jochen Utikal; Brigitte Dreno; Marta Nyakas; Mark R Middleton; Jürgen C Becker; Michelle Casey; Laurie J Sherman; Frank S Wu; Daniele Ouellet; Anne-Marie Martin; Kiran Patel; Dirk Schadendorf
Journal:  N Engl J Med       Date:  2012-06-04       Impact factor: 91.245

Review 2.  Resistance patterns with tyrosine kinase inhibitors in melanoma: new insights.

Authors:  Reinhard Dummer; Keith T Flaherty
Journal:  Curr Opin Oncol       Date:  2012-03       Impact factor: 3.645

3.  Is a single BRAF wild-type test sufficient to exclude melanoma patients from vemurafenib therapy?

Authors:  Mélanie Saint-Jean; Gaëlle Quéreux; Jean-Michel Nguyen; Lucie Peuvrel; Anabelle Brocard; Audrey Vallée; Anne-Chantal Knol; Amir Khammari; Marc G Denis; Brigitte Dréno
Journal:  J Invest Dermatol       Date:  2013-09-11       Impact factor: 8.551

4.  MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study.

Authors:  Paolo A Ascierto; Dirk Schadendorf; Carola Berking; Sanjiv S Agarwala; Carla Ml van Herpen; Paola Queirolo; Christian U Blank; Axel Hauschild; J Thaddeus Beck; Annie St-Pierre; Faiz Niazi; Simon Wandel; Malte Peters; Angela Zubel; Reinhard Dummer
Journal:  Lancet Oncol       Date:  2013-02-13       Impact factor: 41.316

5.  Phase II, open-label, randomized trial of the MEK1/2 inhibitor selumetinib as monotherapy versus temozolomide in patients with advanced melanoma.

Authors:  John M Kirkwood; Lars Bastholt; Caroline Robert; Jeff Sosman; James Larkin; Peter Hersey; Mark Middleton; Mireille Cantarini; Victoria Zazulina; Karin Kemsley; Reinhard Dummer
Journal:  Clin Cancer Res       Date:  2011-11-02       Impact factor: 12.531

6.  High-throughput oncogene mutation profiling in human cancer.

Authors:  Roman K Thomas; Alissa C Baker; Ralph M Debiasi; Wendy Winckler; Thomas Laframboise; William M Lin; Meng Wang; Whei Feng; Thomas Zander; Laura MacConaill; Laura E Macconnaill; Jeffrey C Lee; Rick Nicoletti; Charlie Hatton; Mary Goyette; Luc Girard; Kuntal Majmudar; Liuda Ziaugra; Kwok-Kin Wong; Stacey Gabriel; Rameen Beroukhim; Michael Peyton; Jordi Barretina; Amit Dutt; Caroline Emery; Heidi Greulich; Kinjal Shah; Hidefumi Sasaki; Adi Gazdar; John Minna; Scott A Armstrong; Ingo K Mellinghoff; F Stephen Hodi; Glenn Dranoff; Paul S Mischel; Tim F Cloughesy; Stan F Nelson; Linda M Liau; Kirsten Mertz; Mark A Rubin; Holger Moch; Massimo Loda; William Catalona; Jonathan Fletcher; Sabina Signoretti; Frederic Kaye; Kenneth C Anderson; George D Demetri; Reinhard Dummer; Stephan Wagner; Meenhard Herlyn; William R Sellers; Matthew Meyerson; Levi A Garraway
Journal:  Nat Genet       Date:  2007-02-11       Impact factor: 38.330

7.  Human CD271-positive melanoma stem cells associated with metastasis establish tumor heterogeneity and long-term growth.

Authors:  Gianluca Civenni; Anne Walter; Nikita Kobert; Daniela Mihic-Probst; Marie Zipser; Benedetta Belloni; Burkhardt Seifert; Holger Moch; Reinhard Dummer; Maries van den Broek; Lukas Sommer
Journal:  Cancer Res       Date:  2011-03-10       Impact factor: 12.701

8.  T-helper-1-cell cytokines drive cancer into senescence.

Authors:  Heidi Braumüller; Thomas Wieder; Ellen Brenner; Sonja Aßmann; Matthias Hahn; Mohammed Alkhaled; Karin Schilbach; Frank Essmann; Manfred Kneilling; Christoph Griessinger; Felicia Ranta; Susanne Ullrich; Ralph Mocikat; Kilian Braungart; Tarun Mehra; Birgit Fehrenbacher; Julia Berdel; Heike Niessner; Friedegund Meier; Maries van den Broek; Hans-Ulrich Häring; Rupert Handgretinger; Leticia Quintanilla-Martinez; Falko Fend; Marina Pesic; Jürgen Bauer; Lars Zender; Martin Schaller; Klaus Schulze-Osthoff; Martin Röcken
Journal:  Nature       Date:  2013-02-03       Impact factor: 49.962

9.  Selumetinib plus dacarbazine versus placebo plus dacarbazine as first-line treatment for BRAF-mutant metastatic melanoma: a phase 2 double-blind randomised study.

Authors:  Caroline Robert; Reinhard Dummer; Ralf Gutzmer; Paul Lorigan; Kevin B Kim; Marta Nyakas; Ana Arance; Gabriella Liszkay; Dirk Schadendorf; Mireille Cantarini; Stuart Spencer; Mark R Middleton
Journal:  Lancet Oncol       Date:  2013-06-02       Impact factor: 41.316

10.  Pharmacodynamic effects and mechanisms of resistance to vemurafenib in patients with metastatic melanoma.

Authors:  Kerstin Trunzer; Anna C Pavlick; Lynn Schuchter; Rene Gonzalez; Grant A McArthur; Thomas E Hutson; Stergios J Moschos; Keith T Flaherty; Kevin B Kim; Jeffrey S Weber; Peter Hersey; Georgina V Long; Donald Lawrence; Patrick A Ott; Ravi K Amaravadi; Karl D Lewis; Igor Puzanov; Roger S Lo; Astrid Koehler; Mark Kockx; Olivia Spleiss; Annette Schell-Steven; Houston N Gilbert; Louise Cockey; Gideon Bollag; Richard J Lee; Andrew K Joe; Jeffrey A Sosman; Antoni Ribas
Journal:  J Clin Oncol       Date:  2013-04-08       Impact factor: 44.544
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.